Your browser doesn't support javascript.
loading
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.
Varghese, Abraham M; Rawstron, Andy; Newton, Darren; Tooze, Reuben M; Munir, Talha; Dickson, Marion; Doody, Gina M; Hillmen, Peter.
Afiliação
  • Varghese AM; Department of Haematology, St. James's University Hospital, Leeds, UK.
  • Rawstron A; Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
  • Newton D; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Tooze RM; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Munir T; Department of Haematology, St. James's University Hospital, Leeds, UK.
  • Dickson M; Immunoinflammation Therapy Area, GlaxoSmithKline, Stevenage, UK.
  • Doody GM; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Hillmen P; Department of Haematology, St. James's University Hospital, Leeds, UK.
Br J Haematol ; 182(6): 927-930, 2018 09.
Article em En | MEDLINE | ID: mdl-28770560
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Leucemia Linfocítica Crônica de Células B / Compostos de Anilina Limite: Humans Idioma: En Revista: Br J Haematol Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Leucemia Linfocítica Crônica de Células B / Compostos de Anilina Limite: Humans Idioma: En Revista: Br J Haematol Ano de publicação: 2018 Tipo de documento: Article